Literature DB >> 25218302

Lysophosphatidic acid and signaling in sensory neurons.

Ronald P J Oude Elferink1, Ruth Bolier2, Ulrich H Beuers2.   

Abstract

Lysophosphatidic acid is a potent signaling lipid molecule that has initially been characterized as a growth factor. However, later studies have revealed many more functions such as modulation of cell shape, cell migration, prevention of apoptosis, platelet aggregation, wound healing, osteoclast differentiation, vasopressor activity, embryo implantation, angiogenesis, lung fibrosis, hair growth and more. The molecule mainly acts through the activation of a set of at least 6 G-protein-coupled receptors (LPA1-6), but intracellular LPA was also shown to signal through the activation of the nuclear receptor PPARγ. In this short review we discuss the recent observations which suggest that in pathological conditions LPA also modulates signaling in sensory neurons. Thus, LPA has been shown to play a role in the initiation of neuropathic pain and, more recently, a relation was observed between increased LPA levels in the circulation and cholestatic itch. The mechanism by which this occurs remains to be elucidated. This article is part of a Special Issue entitled Linking transcription to physiology in lipodomics.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autotaxin; Cholestasis; Lysophosphatidic acid; Neuropathic pain; Pruritus

Mesh:

Substances:

Year:  2014        PMID: 25218302     DOI: 10.1016/j.bbalip.2014.09.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

2.  Downregulation of Spinal G Protein-Coupled Kinase 2 Abolished the Antiallodynic Effect of Electroacupuncture.

Authors:  Huan Liu; Shen-Bin Liu; Qian Li; Huijing Wang; Yan-Qing Wang; Qi-Liang Mao-Ying
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-29       Impact factor: 2.629

3.  Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis.

Authors:  Chunwei Zeng; Bo Wen; Guixue Hou; Li Lei; Zhanlong Mei; Xuekun Jia; Xiaomin Chen; Wu Zhu; Jie Li; Yehong Kuang; Weiqi Zeng; Juan Su; Siqi Liu; Cong Peng; Xiang Chen
Journal:  Gigascience       Date:  2017-10-01       Impact factor: 6.524

4.  Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis.

Authors:  Kentaro Hayakawa; Makoto Kurano; Junichi Ohya; Takeshi Oichi; Kuniyuki Kano; Masako Nishikawa; Baasanjav Uranbileg; Ken Kuwajima; Masahiko Sumitani; Sakae Tanaka; Junken Aoki; Yutaka Yatomi; Hirotaka Chikuda
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

Review 5.  PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases.

Authors:  Márcia V de Carvalho; Cassiano F Gonçalves-de-Albuquerque; Adriana R Silva
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

6.  An LPAR 5 -antagonist that reduces nociception and increases pruriception.

Authors:  Jacqueline Langedijk; Erika Ivanna Araya; Amanda Ribeiro Barroso; Dagmar Tolenaars; Marc Nazaré; Hassane Belabed; Jens Schoene; Juliana Geremias Chichorro; Ronald Oude Elferink
Journal:  Front Pain Res (Lausanne)       Date:  2022-07-26

7.  Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats.

Authors:  Jing-Xiang Wu; Xiao-Min Yuan; Qiong Wang; Wang Wei; Mei-Ying Xu
Journal:  Mol Pain       Date:  2016-04-18       Impact factor: 3.395

8.  Lipidomic Profiling Identifies Serum Lipids Associated with Persistent Multisite Musculoskeletal Pain.

Authors:  Canchen Ma; Ming Liu; Jing Tian; Guangju Zhai; Flavia Cicuttini; Yvette L Schooneveldt; Peter J Meikle; Graeme Jones; Feng Pan
Journal:  Metabolites       Date:  2022-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.